0% found this document useful (0 votes)
7 views32 pages

Understanding Polycystic Ovary Syndrome (PCOS)

Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
0% found this document useful (0 votes)
7 views32 pages

Understanding Polycystic Ovary Syndrome (PCOS)

Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd

Topic

Polycystic ovary syndrome


(PCOS)

Extern Thanatchaporn Puangnak


Rotate D1 61460414
Definition
■ Polycystic ovary syndrome (PCOS) is the most common
endocrinopathy affecting reproductive-aged women, with impacts
across the lifespan from adolescence to post menopause

■ PCOS is believed to be a multifactorial disorder of both genetic and


environmental factors
Pathophysiology
■ Unknown cause
■ Multifactorial and polygenic
■ Genetic basis suspected
- Androgen synthesis : CYP11A gene, CYP17A gene
- Insulin resistance : insulin receptor gene on chromosome 19p13.2
■ Predisposing factors
- Family history of PCOS
- High maternal androgen
- Onset DM type I before menarche
- Insulin resistance
- Obesity
Pathophysiology
Sign and symptoms
■ Menstrual dysfunction
- Amenorrhea
- Oligomenorrhea
- Menometrorrhagia

■ Hyperandrogenism
- Hirsutism: terminal hairs, male pattern, Acne
- Androgenic alopecia

■ Insulin resistance
- Acanthosis nigricans
- Common in obesity patient

■ Infertility
- Anovulation,
- Abortion,
- GDM, PIH
Hyperandrogenism: Hirsutism
Ludwig or Olsen
visual scales
Insulin resistance - Acanthosis nigrican
Diagnosis
Diagnosis: ESHRE 2023
Diagnosis
Diagnosis
Biochemical
hyperandrogenism
Diagnosis Ultrasound

■ Follicle number per ovary (FNPO) ≥ 20 in at least one ovary


■ Follicle number per cross-section (FNPS) ≥ 10 in at least one ovary
■ Ovarian volume (OV) ≥ 10 mL at least one ovary
■ TVS more accurate than TAS
■ TAS same criteria as TVS but in either ovary
Diagnosis Ultrasound

■ Polycystic ovary
■ ≥ 10 small follicles, placed
peripherally, each follicle size
2-9 mm → string of pearls
■ Ovarian enlargement
■ Rules out ovarian tumor
Differential
diagnosis
Consequences of
PCOS
Consequences of PCOS: Investigation
■ Obesity: BMI, waist circumference
■ Hypertension: BP
■ Insulin resistance: 75 g OGTT, FBS
■ Indication:
- Age> 40 yr
- BMI >31 kg/m2
- Acanthosis nigricans,
- Hx GDM
- Family history of Type 2 DM
■ Dyslipidemia: Lipid profile
■ Mood disorder
■ Other: Fatty liver, Sleep apnea
Cardiovascular risk
Long term assessment for PCOS patient
■ Waist circumference and BMI : every visit
■ Blood pressure: every visit
■ Lipid profile: If normal, assess every 2 years or sooner if weight gain
■ 75 g OGTT: If normal, assess every 2 years or sooner if additional risk
factors present
Management
Lifestyle modification

■ Weight management reduce 5-10%, waist circumference<80cm


■ Diet control: reduce 500-1000 kcal/day
■ Exercise:
- Moderate intensity, 150-300 minutes/weeks
- Vigorous intensity, 75-150 minutes/weeks
Combined oral contraceptives
■ COCP is recommended in reproductive age adults for
management of hirsutism and/or irregular menstrual cycles
■ Reduced Hyperandrogenism
■ Reduced risk of endometrial hyperplasia
■ Progestin with low androgenic activity
- Norethindrone
- Norgestimate
- Desogestrel
- Drospirenone
- Cyproterone acetate
Cyclic progestins

■ 10-14 days/month
■ Medroxyprogesterone acetate (MPA) 5-10 mg/day
■ Micronized progesterone 200 mg/day
Insulin sensitizing agents (Metformin)
■ Reduced Insulin resistance:
- Reduced hepatic glucose production,
- increased Insulin sensitivity
- Reduced Androgen
■ Start low dose (500 mg/day) → 1,500-2,000 mg/day
■ ADR:
- GI symptom (nausea, vomiting, diarrhea)
- Lactic acidosis
■ Use in BMI ≥ 25 kg/m
COCP vs Metformin

■ COCP > metformin : hirsutism in irregular menstrual cycles


■ Metformin > COCP for metabolic indications of PCOS
■ Indication of combination therapy:
- High metabolic risk groups (BMI > 30kg/m2)
- Diabetes risk factors,
- Impaired glucose tolerance or high-risk ethnic groups
Treatment hirsutism: Medication
■ Combined oral contraceptives

■ Eflornithine hydrochloride (irreversible inhibitor of ornithine


decarboxylase)

■ Androgen-receptor antagonist
- Spironolactone 25-100 mg/day
- Cyproterone acetate 50-100 mg/day
- Flutamide 125-250 mg/day

■ 5α-reductase inhibitors : Finasteride รับประทาน 2.5-5 mg/day


Treatment hirsutism: Cosmetic

■ Depilation (Hair removal above skin surface)


- shaving, topical chemical depilatory agent

■ Epilation (Remove the entire hair shaft and root)


- plucking, waxing, threading, electrolysis, laser

■ Bleaching
Treatment Acne

■ Combined oral contraceptives (COC)

■ Antiandrogens
- Spironolactone
- Flutamide

■ 5α-reductase inhibitors
- Finasteride
Treatment
infertility
References

You might also like